Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.1371/journal.pone.0049845 |
Resumo: | The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients with a documented infection and treated with piperacillin/tazobactam admitted to one of the participating ICU between 2006 and 2010. We successfully matched 173 pairs of patients according to whether they received continuous or conventional intermittent dosing of piperacillin/tazobactam, using a propensity score to adjust for confounding variables. The majority of patients received 16g/day of piperacillin plus 2g/day of tazobactam. The 28-day mortality rate was 28.3% in both groups (p = 1.0). The ICU and in-hospital mortality were also similar either in those receiving continuous infusion or intermittent dosing (23.7% vs. 20.2%, p = 0.512 and 41.6% vs. 40.5%, p = 0.913, respectively). In the subgroup of patients with a Simplified Acute Physiology Score (SAPS) II>42, the 28-day mortality rate was lower in the continuous infusion group (31.4% vs. 35.2%) although not reaching significance (p = 0.66). We concluded that the clinical efficacy of piperacillin/tazobactam in this heterogeneous group of critically ill patients infected with susceptible bacteria was independent of its mode of administration, either continuous infusion or intermittent dosing. |
id |
RCAP_1b41a940933e96fa967f00c9470694f3 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/22461 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched AnalysisCARE-UNIT PATIENTSINTENSIVE-CARECONTROLLED-TRIALSBETA-LACTAMSANTIBIOTICSCEFEPIMECLEARANCEPHARMACOKINETICSMETAANALYSISTAZOBACTAMAgricultural and Biological Sciences(all)Biochemistry, Genetics and Molecular Biology(all)Medicine(all)The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients with a documented infection and treated with piperacillin/tazobactam admitted to one of the participating ICU between 2006 and 2010. We successfully matched 173 pairs of patients according to whether they received continuous or conventional intermittent dosing of piperacillin/tazobactam, using a propensity score to adjust for confounding variables. The majority of patients received 16g/day of piperacillin plus 2g/day of tazobactam. The 28-day mortality rate was 28.3% in both groups (p = 1.0). The ICU and in-hospital mortality were also similar either in those receiving continuous infusion or intermittent dosing (23.7% vs. 20.2%, p = 0.512 and 41.6% vs. 40.5%, p = 0.913, respectively). In the subgroup of patients with a Simplified Acute Physiology Score (SAPS) II>42, the 28-day mortality rate was lower in the continuous infusion group (31.4% vs. 35.2%) although not reaching significance (p = 0.66). We concluded that the clinical efficacy of piperacillin/tazobactam in this heterogeneous group of critically ill patients infected with susceptible bacteria was independent of its mode of administration, either continuous infusion or intermittent dosing.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)RUNGonçalves-Pereira, JoãoOliveira, Bruno SerraJaneiro, SérgioEstilita, JoanaMonteiro, CatarinaSalgueiro, AndreaVieira, AlfredoGouveia, JoaoPaulino, CarolinaBento, LuisPóvoa, Pedro2017-08-03T22:05:11Z2012-11-212012-11-21T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.1371/journal.pone.0049845eng1932-6203PURE: 2991230http://www.scopus.com/inward/record.url?scp=84869853144&partnerID=8YFLogxKhttps://doi.org/10.1371/journal.pone.0049845info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:10:09Zoai:run.unl.pt:10362/22461Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:27:18.863142Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis |
title |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis |
spellingShingle |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis Gonçalves-Pereira, João CARE-UNIT PATIENTS INTENSIVE-CARE CONTROLLED-TRIALS BETA-LACTAMS ANTIBIOTICS CEFEPIME CLEARANCE PHARMACOKINETICS METAANALYSIS TAZOBACTAM Agricultural and Biological Sciences(all) Biochemistry, Genetics and Molecular Biology(all) Medicine(all) |
title_short |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis |
title_full |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis |
title_fullStr |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis |
title_full_unstemmed |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis |
title_sort |
Continuous Infusion of Piperacillin/Tazobactam in Septic Critically Ill Patients-A Multicenter Propensity Matched Analysis |
author |
Gonçalves-Pereira, João |
author_facet |
Gonçalves-Pereira, João Oliveira, Bruno Serra Janeiro, Sérgio Estilita, Joana Monteiro, Catarina Salgueiro, Andrea Vieira, Alfredo Gouveia, Joao Paulino, Carolina Bento, Luis Póvoa, Pedro |
author_role |
author |
author2 |
Oliveira, Bruno Serra Janeiro, Sérgio Estilita, Joana Monteiro, Catarina Salgueiro, Andrea Vieira, Alfredo Gouveia, Joao Paulino, Carolina Bento, Luis Póvoa, Pedro |
author2_role |
author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Centro de Estudos de Doenças Crónicas (CEDOC) RUN |
dc.contributor.author.fl_str_mv |
Gonçalves-Pereira, João Oliveira, Bruno Serra Janeiro, Sérgio Estilita, Joana Monteiro, Catarina Salgueiro, Andrea Vieira, Alfredo Gouveia, Joao Paulino, Carolina Bento, Luis Póvoa, Pedro |
dc.subject.por.fl_str_mv |
CARE-UNIT PATIENTS INTENSIVE-CARE CONTROLLED-TRIALS BETA-LACTAMS ANTIBIOTICS CEFEPIME CLEARANCE PHARMACOKINETICS METAANALYSIS TAZOBACTAM Agricultural and Biological Sciences(all) Biochemistry, Genetics and Molecular Biology(all) Medicine(all) |
topic |
CARE-UNIT PATIENTS INTENSIVE-CARE CONTROLLED-TRIALS BETA-LACTAMS ANTIBIOTICS CEFEPIME CLEARANCE PHARMACOKINETICS METAANALYSIS TAZOBACTAM Agricultural and Biological Sciences(all) Biochemistry, Genetics and Molecular Biology(all) Medicine(all) |
description |
The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese intensive care units (ICU). We included 569 critically ill adult patients with a documented infection and treated with piperacillin/tazobactam admitted to one of the participating ICU between 2006 and 2010. We successfully matched 173 pairs of patients according to whether they received continuous or conventional intermittent dosing of piperacillin/tazobactam, using a propensity score to adjust for confounding variables. The majority of patients received 16g/day of piperacillin plus 2g/day of tazobactam. The 28-day mortality rate was 28.3% in both groups (p = 1.0). The ICU and in-hospital mortality were also similar either in those receiving continuous infusion or intermittent dosing (23.7% vs. 20.2%, p = 0.512 and 41.6% vs. 40.5%, p = 0.913, respectively). In the subgroup of patients with a Simplified Acute Physiology Score (SAPS) II>42, the 28-day mortality rate was lower in the continuous infusion group (31.4% vs. 35.2%) although not reaching significance (p = 0.66). We concluded that the clinical efficacy of piperacillin/tazobactam in this heterogeneous group of critically ill patients infected with susceptible bacteria was independent of its mode of administration, either continuous infusion or intermittent dosing. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-11-21 2012-11-21T00:00:00Z 2017-08-03T22:05:11Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.1371/journal.pone.0049845 |
url |
https://doi.org/10.1371/journal.pone.0049845 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1932-6203 PURE: 2991230 http://www.scopus.com/inward/record.url?scp=84869853144&partnerID=8YFLogxK https://doi.org/10.1371/journal.pone.0049845 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137901692321792 |